Sonoma Pharmaceuticals Overview
Latest ROE for Sonoma Pharmaceuticals: -34.33% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-34.33%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Sonoma Pharmaceuticals (SNOA) currently reports a ROE of -34.33%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Sonoma Pharmaceuticals's ROE history and peer comparisons.
Sonoma Pharmaceuticals's ROE of -34.33% is lower than the Healthcare sector average of 20.86%. That is roughly 264.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Sonoma Pharmaceuticals's current -34.33% should be judged against Healthcare norms (sector average: 20.86%) and against SNOA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -34.33%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Sonoma Pharmaceuticals, and consider following SNOA for alerts when major investors trade the stock.
Sonoma Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -34.33% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNOA with unrelated industries.
